ARQ 531
99%
- Product Code: 63196
CAS:
2095393-15-8
| Molecular Weight: | 478.93 g./mol | Molecular Formula: | C₂₅H₂₃ClN₄O₄ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20℃ |
Product Description:
ARQ 531 is primarily investigated for its potential in treating various cancers, particularly those involving B-cell malignancies and solid tumors. It functions as a reversible inhibitor of Bruton's tyrosine kinase (BTK), which plays a critical role in B-cell receptor signaling. By targeting BTK, ARQ 531 disrupts the survival and proliferation of cancerous B-cells. Additionally, it has shown efficacy in overcoming resistance to other BTK inhibitors, making it a promising candidate for patients who have developed resistance to first-generation therapies like ibrutinib. Its broad-spectrum activity also extends to other kinases, potentially expanding its therapeutic applications. Ongoing clinical trials aim to evaluate its safety, tolerability, and effectiveness in treating relapsed or refractory hematologic cancers.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | $67.51 |
+
-
|
| 0.010 | 10-20 days | $116.11 |
+
-
|
| 0.025 | 10-20 days | $257.07 |
+
-
|
| 0.100 | 10-20 days | $657.79 |
+
-
|
ARQ 531
ARQ 531 is primarily investigated for its potential in treating various cancers, particularly those involving B-cell malignancies and solid tumors. It functions as a reversible inhibitor of Bruton's tyrosine kinase (BTK), which plays a critical role in B-cell receptor signaling. By targeting BTK, ARQ 531 disrupts the survival and proliferation of cancerous B-cells. Additionally, it has shown efficacy in overcoming resistance to other BTK inhibitors, making it a promising candidate for patients who have developed resistance to first-generation therapies like ibrutinib. Its broad-spectrum activity also extends to other kinases, potentially expanding its therapeutic applications. Ongoing clinical trials aim to evaluate its safety, tolerability, and effectiveness in treating relapsed or refractory hematologic cancers.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
$0.00
$0.00
Total :